Clinical efficacy and pharmaceutical analysis of rebamipide combined with pantoprazole in the treatment of Helicobacter pylori-negative chronic erosive gastritis
Objective To study the clinical efficacy of rebamipide combined with pantoprazole in the treatment of Helicobacter pylori(Hp)-negative chronic erosive gastritis.Methods A trial was conducted on 85 patients with Hp-negative chronic erosive gastritis admitted to Bayannur Hospital from March 2020 to January 2023.They were randomly divided into a trial group of 42 cases and a reference group of 43 cases according to the envelope method.The trial group was treated with rebamipide combined with pantoprazole,while the reference group was treated with rebamipide combined with sucralfate.The clinical efficacy,the levels of malondialdehyde(MDA)and prostaglandin E2(PGE2)in the gastric mucosa before and after treatment,the levels of serological indicators before and after treatment,and adverse reactions of the two groups were compared.Results The total effective rate of the trial group was higher than that of the reference group(97.62％vs.83.72％)(P<0.05).There was no statistically significant difference in MDA and PGE2 levels between the two groups before treatment(P>0.05).After 8 weeks of treatment,the MDA level in the trial group was lower than that in the reference group,while the PGE2 level was higher than that in the reference group,with statistically significant differences(P<0.05).There were no statistically significant differences in the levels of serum vasoactive intestinal peptide(VIP)and ghrelin between the two groups before treatment(P>0.05).After 8 weeks of treatment,the serum VIP level in the trial group was lower than that in the reference group,while the ghrelin level was higher than that in the reference group(P<0.05).The total incidence of adverse reactions in the trial group was lower than that in the reference group(4.76％vs.18.60％)(P<0.05).Conclusion The combination of rebamipide and pantoprazole has a significant efficacy on patients with Hp-negative chronic erosive gastritis,which can improve the levels of VIP and ghrelin in erosive tissues and serum,reduce the risk of adverse reactions,and is worthy of promotion and application.
万方数据
维普
